Company
Intrommune Therapeutics
is developing easy-to-use oral products containing food proteins, making allergen exposure as easy as brushing your teeth.
Also known as Intrommune Therapeutics, Inc.
- Status
- Operatingas of 2026-09-19
- Headquarters
- New York City, New York, United States
- Legal name
- Intrommune Therapeutics, Inc.
- intrommune.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
Intrommune is a New York City-based biotechnology company dedicated to simplifying allergy immunotherapy.
Funding snapshot
- Total raised
- $3.6MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $210K2023-12-06
Funding rounds
- Round, 2023
- $210K2023-12-06, SEC form D sold, 7 investors
- Round, 2022
- $3.3M2022-03-16, SEC form D sold, 15 investors
- Round, 2021
- $68K2021-07-02, SEC form D sold, 6 investors
- Round, 2018
- 2018-04-12
Loading relationship preview